Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Assets: 2022-2025

Historic Assets for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $316.6 million.

  • Taysha Gene Therapies' Assets rose 75.65% to $316.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.6 million, marking a year-over-year increase of 75.65%. This contributed to the annual value of $160.4 million for FY2024, which is 7.16% down from last year.
  • Taysha Gene Therapies' Assets amounted to $316.6 million in Q3 2025, which was down 5.03% from $333.3 million recorded in Q2 2025.
  • Taysha Gene Therapies' Assets' 5-year high stood at $333.3 million during Q2 2025, with a 5-year trough of $81.5 million in Q2 2023.
  • Moreover, its 3-year median value for Assets was $172.7 million (2023), whereas its average is $184.9 million.
  • Per our database at Business Quant, Taysha Gene Therapies' Assets crashed by 42.71% in 2023 and then soared by 145.75% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Assets (Quarterly) stood at $126.3 million in 2022, then soared by 36.79% to $172.7 million in 2023, then declined by 7.16% to $160.4 million in 2024, then skyrocketed by 75.65% to $316.6 million in 2025.
  • Its last three reported values are $316.6 million in Q3 2025, $333.3 million for Q2 2025, and $138.4 million during Q1 2025.